Atea Pharmaceuticals (AVIR) Insider Berman Buys 37,700 Shares

Howard Berman Adds to Holdings at Atea Pharmaceuticals

Howard Berman picked up 37,700 shares of Atea Pharmaceuticals, Inc. (NasdaqGS: AVIR) on June 18, 2026. This purchase stands out due to its size relative to typical individual transactions at the firm, adding a notable block of stock to the insider's personal holdings during a wide round of mid-year trading.

A Busy Day of Insider Transactions

The June 18 trading session brought a flurry of movement among company insiders, featuring a mix of acquisitions and dispositions across the roster. Bruce Polsky bought 29,600 shares on the same day, while Franklin Berger also acquired 29,600 shares. On the other side of the ledger, Polly Murphy disposed of 29,600 shares, and Franklin Berger executed a separate sale of 29,600 shares. Bruno Lucidi was similarly active, parting with 29,600 shares while simultaneously picking up 26,700 shares in a separate transaction on June 18, 2026.

AVIR Stock Performance and Market Context

Shares of the clinical-stage biotech firm trade around $4.48, sitting within a 52-week band defined by a low of $2.78 and a high of $6.45. The company carries a market capitalization of roughly $434.5 million. Its moving averages show the stock changing hands near the 200-day mark of $4.72 and slightly below the 50-day moving average of $5.13.

Analysts Set New Price Targets

Wall Street firms continue to monitor the clinical-stage company closely. On August 13, 2026, Morgan Stanley maintained its Equal-Weight rating on the stock while lifting its price target to $7.00 from a previous target of $6.00. Across the wider analyst community, the equity holds a consensus target mean price of $9.42, with projections ranging from a low of $7.00 up to $11.25 based on three analyst opinions.

Inside Atea Pharmaceuticals

Atea Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company focused on discovering and developing oral antiviral drug candidates for serious viral infections. Headquartered in Boston, Massachusetts, the firm advances therapies targeting hepatitis C and other viral conditions using a proprietary platform of nucleosides and nucleotides.

What to Watch at AVIR

Market participants will look toward the company's upcoming financial updates and further Form 4 filings for additional cues on insider sentiment. The firm is scheduled to report its next round of quarterly earnings on November 11, 2026.